查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球多發性骨髓瘤治療市場：增長、展望、競爭分析 (2022-2030)
市場調查報告書
商品編碼
1180684

全球多發性骨髓瘤治療市場：增長、展望、競爭分析 (2022-2030)

Multiple Myeloma Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

全球多發性骨髓瘤治療市場預計將在 2021 年增長，原因包括患病率上升、對癌症早期診斷和治療的高度認識、支持性報銷政策以及醫療基礎設施的發展北美佔最大份額到因素。 預計在不久的將來，對新型藥物療法的需求將會增加。 預計亞太地區將成為 2022-2030 年預測期內增長最快的地區。

本報告考察了全球多發性骨髓瘤治療市場，並提供了有關競爭分析、宏觀分析和市場動態、按類型和地區劃分的市場分析、公司概況等方面的信息。

內容

第一章前言

  • 報告說明
  • 市場細分
  • 調查方法

第 2 章執行摘要

  • 市場概況：全球多發性骨髓瘤治療市場
  • 全球多發性骨髓瘤治療市場：按類型分類，2021 年（百萬美元）
  • 全球多發性骨髓瘤治療市場：按地區劃分，2021 年（百萬美元）
  • 有吸引力的投資建議：按地區劃分，2021 年

第 3 章多發性骨髓瘤治療市場：競爭分析

  • 主要多發性骨髓瘤治療市場供應商的市場定位
  • 市場供應商採用的多發性骨髓瘤治療策略
  • 主要行業戰略
  • 分層分析：2021 年與 2030 年

第 4 章多發性骨髓瘤治療市場：宏觀分析和市場動態

  • 簡介
  • 全球多發性骨髓瘤治療市場價值：2020-2030 年（百萬美元）
  • 市場動態
    • 市場驅動力
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章多發性骨髓瘤治療市場：按類型（2020-2030，百萬美元）

  • 市場概覽
  • 增長和收益分析：2021 年與 2030 年
  • 市場細分
    • 藥物治療
    • 幹細胞移植
    • 生物膦酸鹽
    • 放射治療
    • 手術治療

第 6 章。北美多發性骨髓瘤治療市場：2020-2030 年，100 萬美元

  • 市場概覽
  • 按類型（2020-2030 年，百萬美元）
  • 按地區（2020-2030 年，百萬美元）
    • 北美

第 7 章。英國/歐盟多發性骨髓瘤治療市場：2020-2030 年，百萬美元

  • 市場概覽
  • 按類型（2020-2030 年，百萬美元）
  • 按地區（2020-2030 年，百萬美元）
    • 英國/歐盟

第 8 章亞太多發性骨髓瘤治療市場：2020-2030 年，百萬美元

  • 市場概覽
  • 按類型（2020-2030 年，百萬美元）
  • 按地區（2020-2030 年，百萬美元）
    • 亞太地區

第 9 章。拉丁美洲多發性骨髓瘤治療市場：2020-2030 年，百萬美元

  • 市場概覽
  • 按類型（2020-2030 年，百萬美元）
  • 按地區（2020-2030 年，百萬美元）
    • 拉丁美洲

第 10 章中東和非洲多發性骨髓瘤治療市場：2020-2030 年，百萬美元

  • 市場概覽
  • 按類型（2020-2030 年，百萬美元）
  • 按地區（2020-2030 年，百萬美元）
    • 中東和非洲

第11章公司簡介

  • Janssen Biotech, Inc.
  • Bristol-Myers Squibb
  • Novartis AG
  • Millennium Pharmaceuticals
  • Celgene Corporation
  • Kesios Therapeutics Limited
  • Amgen, Inc.
  • Genzyme Corporation
  • Juno Therapeutics
  • Abbvie, Inc.
  • Array BioPharma
  • Karyopharm Therapeutics
  • Merck KGaA
  • Sanofi S.A
  • Takeda Pharmaceutical Industries Ltd.
Product Code: 137239-08-22

The report titled "Multiple Myeloma Treatment Market- Growth, Future Prospects, and Competitive Analysis, 2022 - 2030" offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration of 2020 to 2030. The said research study cover in-depth analysis of multiple myeloma market segments based on type and different geographies further segmented by countries. According to myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably and release only one type of antibody known as paraprotein, which has no useful function. It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.

For the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into Drug Therapy, Stem cell Transplantation, Biophosphonates, Radiation Therapy, & Surgical Therapy. Drug therapy is further segmented into monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors, chemotherapy, histone deacetylase inhibitor, and corticosteroids.

The geographical segmentation of multiple myeloma treatment market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries.

The multiple myeloma treatment market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, Juno Therapeutics, among others.

In year 2021, drug therapy dominated the market due to incessant market entry of novel drug therapies, most convenient mode of treatment, and rising demand for targeted therapy/ biological drugs. These drugs enhance the immune system cells that identify and attack cancer cells. The biologic therapies are expected to benefit from the rising preference among medical practitioners to implement biologics owing to their established clinical profile. Recently, the approval of new monoclonal antibodies, such as Darzalex, Pomalyst and Empliciti, are anticipated to drive the growth of this market segment in the near future. Furthermore, in August 2017 FDA approved personalized cellular therapy for advanced leukemia named chimeric antigen receptor (CAR) T-cell therapy is under clinical trials for multiple myeloma and its approval is expected to boost the growth of multiple myeloma treatment market in the near future.

In base year 2021, North America accounted for the largest share in global multiple myeloma treatment market due to key driving factors such as rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure. The American Cancer Society estimates that in 2017 about 30,280 new cases will be diagnosed in the United States and about 12,590 deaths are expected to occur. Thus, demand for novel drug therapies are expected to increase in the near future. During forecast period 2022 - 2030, Asia Pacific was observed as the fastest growing region due to key driving factors such as rising prevalence of multiple myeloma in developing countries, increasing awareness associated with early cancer diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Multiple Myeloma Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Multiple Myeloma Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

Drugs Therapy

Monoclonal Antibodies

Daratumumab

Elotuzumab

Immunomodulatory Drugs

Lenalidomide

Pomalidomide

Thalidomide

Proteasome Inhibitors

Ixazomib

Bortezomib

Carfilzomib

Chemotherapy

Doxorubicin HCl liposome

Melphalan

Cyclophosphamide

Histone deacetylase inhibitor

Panobinostat

Corticosteroids

Dexamethasone

Prednisone

Stem Cell Transplantation

Allogenic Stem Cell Transplants

Autologous Stem Cell Transplants

Biophosphonates

Radiation Therapy

Surgical Therapy

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Multiple Myeloma Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Multiple Myeloma Treatment market?

Which is the largest regional market for Multiple Myeloma Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Multiple Myeloma Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Multiple Myeloma Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Multiple Myeloma Treatment Market
  • 2.2. Global Multiple Myeloma Treatment Market, By Type, 2021 (US$ Million)
  • 2.3. Global Multiple Myeloma Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Multiple Myeloma Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Multiple Myeloma Treatment Market Vendors
  • 3.2. Strategies Adopted by Multiple Myeloma Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Multiple Myeloma Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Multiple Myeloma Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Drugs Therapy
      • 5.3.1.1. Monoclonal Antibodies
        • 5.3.1.1.1. Daratumumab
        • 5.3.1.1.2. Elotuzumab
      • 5.3.1.2. Immunomodulatory Drugs
        • 5.3.1.2.1. Lenalidomide
        • 5.3.1.2.2. Pomalidomide
        • 5.3.1.2.3. Thalidomide
      • 5.3.1.3. Proteasome Inhibitors
        • 5.3.1.3.1. Ixazomib
        • 5.3.1.3.2. Bortezomib
        • 5.3.1.3.3. Carfilzomib
      • 5.3.1.4. Chemotherapy
        • 5.3.1.4.1. Doxorubicin HCl liposome
        • 5.3.1.4.2. Melphalan
        • 5.3.1.4.3. Cyclophosphamide
      • 5.3.1.5. Histone deacetylase inhibitor
        • 5.3.1.5.1. Panobinostat
      • 5.3.1.6. Corticosteroids
        • 5.3.1.6.1. Dexamethasone
        • 5.3.1.6.2. Prednisone
    • 5.3.2. Stem Cell Transplantation
      • 5.3.2.1. Allogenic Stem Cell Transplants
      • 5.3.2.2. Autologous Stem Cell Transplants
    • 5.3.3. Biophosphonates
    • 5.3.4. Radiation Therapy
    • 5.3.5. Surgical Therapy

6. North America Multiple Myeloma Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
  • 6.3.Multiple Myeloma Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)

7. UK and European Union Multiple Myeloma Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
  • 7.3.Multiple Myeloma Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)

8. Asia Pacific Multiple Myeloma Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
  • 8.3.Multiple Myeloma Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)

9. Latin America Multiple Myeloma Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
  • 9.3.Multiple Myeloma Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)

10. Middle East and Africa Multiple Myeloma Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
  • 10.3.Multiple Myeloma Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Janssen Biotech, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bristol-Myers Squibb
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Novartis AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Millennium Pharmaceuticals
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Celgene Corporation
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Kesios Therapeutics Limited
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Amgen, Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Genzyme Corporation
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Juno Therapeutics
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Abbvie, Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Array BioPharma
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Karyopharm Therapeutics
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Merck KGaA
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Sanofi S.A
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives
  • 11.15. Takeda Pharmaceutical Industries Ltd.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Portfolio
    • 11.15.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 2 Global Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 3 Global Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 4 Global Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 5 Global Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 6 Global Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 7 Global Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 8 Global Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 9 Global Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 10 North America Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 11 North America Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 12 North America Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 13 North America Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 14 North America Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 15 North America Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 16 North America Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 17 North America Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 18 North America Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 19 U.S. Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 20 U.S. Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 21 U.S. Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 22 U.S. Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 23 U.S. Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 24 U.S. Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 25 U.S. Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 26 U.S. Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 27 U.S. Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 28 Canada Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 29 Canada Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 30 Canada Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 31 Canada Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 32 Canada Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 33 Canada Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 34 Canada Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 35 Canada Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 36 Canada Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 37 Rest of North America Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 38 Rest of North America Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 39 Rest of North America Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 40 Rest of North America Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 41 Rest of North America Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 42 Rest of North America Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 43 Rest of North America Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 44 Rest of North America Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 45 Rest of North America Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 46 UK and European Union Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 47 UK and European Union Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 48 UK and European Union Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 49 UK and European Union Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 50 UK and European Union Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 51 UK and European Union Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 52 UK and European Union Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 53 UK and European Union Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 54 UK and European Union Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 55 UK Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 56 UK Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 57 UK Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 58 UK Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 59 UK Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 60 UK Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 61 UK Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 62 UK Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 63 UK Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 64 Germany Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 65 Germany Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 66 Germany Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 67 Germany Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 68 Germany Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 69 Germany Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 70 Germany Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 71 Germany Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 72 Germany Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 73 Spain Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 74 Spain Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 75 Spain Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 76 Spain Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 77 Spain Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 78 Spain Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 79 Spain Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 80 Spain Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 81 Spain Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 82 Italy Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 83 Italy Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 84 Italy Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 85 Italy Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 86 Italy Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 87 Italy Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 88 Italy Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 89 Italy Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 90 Italy Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 91 France Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 92 France Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 93 France Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 94 France Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 95 France Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 96 France Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 97 France Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 98 France Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 99 France Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 100 Rest of Europe Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 101 Rest of Europe Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 102 Rest of Europe Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 103 Rest of Europe Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 104 Rest of Europe Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 105 Rest of Europe Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 106 Rest of Europe Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 107 Rest of Europe Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 108 Rest of Europe Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 109 Asia Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 110 Asia Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 111 Asia Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 112 Asia Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 113 Asia Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 114 Asia Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 115 Asia Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 116 Asia Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 117 Asia Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 118 China Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 119 China Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 120 China Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 121 China Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 122 China Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 123 China Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 124 China Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 125 China Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 126 China Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 127 Japan Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 128 Japan Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 129 Japan Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 130 Japan Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 131 Japan Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 132 Japan Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 133 Japan Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 134 Japan Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 135 Japan Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 136 India Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 137 India Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 138 India Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 139 India Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 140 India Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 141 India Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 142 India Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 143 India Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 144 India Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 145 Australia Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 146 Australia Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 147 Australia Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 148 Australia Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 149 Australia Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 150 Australia Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 151 Australia Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 152 Australia Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 153 Australia Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 154 South Korea Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 155 South Korea Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 156 South Korea Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 157 South Korea Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 158 South Korea Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 159 South Korea Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 160 South Korea Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 161 South Korea Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 162 South Korea Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 163 Latin America Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 164 Latin America Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 165 Latin America Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 166 Latin America Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 167 Latin America Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 168 Latin America Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 169 Latin America Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 170 Latin America Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 171 Latin America Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 172 Brazil Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 173 Brazil Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 174 Brazil Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 175 Brazil Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 176 Brazil Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 177 Brazil Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 178 Brazil Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 179 Brazil Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 180 Brazil Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 181 Mexico Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 182 Mexico Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 183 Mexico Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 184 Mexico Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 185 Mexico Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 186 Mexico Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 187 Mexico Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 188 Mexico Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 189 Mexico Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 190 Rest of Latin America Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 191 Rest of Latin America Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 192 Rest of Latin America Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 193 Rest of Latin America Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 194 Rest of Latin America Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 195 Rest of Latin America Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 196 Rest of Latin America Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 197 Rest of Latin America Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 198 Rest of Latin America Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 199 Middle East and Africa Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 200 Middle East and Africa Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 201 Middle East and Africa Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 202 Middle East and Africa Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 203 Middle East and Africa Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 204 Middle East and Africa Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 205 Middle East and Africa Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 206 Middle East and Africa Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 207 Middle East and Africa Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 208 GCC Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 209 GCC Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 210 GCC Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 211 GCC Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 212 GCC Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 213 GCC Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 214 GCC Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 215 GCC Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 216 GCC Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 217 Africa Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 218 Africa Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 219 Africa Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 220 Africa Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 221 Africa Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 222 Africa Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 223 Africa Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 224 Africa Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 225 Africa Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)
  • TABLE 226 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Type, 2020-2030, USD (Million)
  • TABLE 227 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Drugs Therapy, 2020-2030, USD (Million)
  • TABLE 228 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Monoclonal Antibodies, 2020-2030, USD (Million)
  • TABLE 229 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 230 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Proteasome Inhibitors, 2020-2030, USD (Million)
  • TABLE 231 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Chemotherapy, 2020-2030, USD (Million)
  • TABLE 232 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Histone deacetylase inhibitor, 2020-2030, USD (Million)
  • TABLE 233 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
  • TABLE 234 Rest of Middle East and Africa Multiple Myeloma Treatment Market By Stem Cell Transplantation, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Multiple Myeloma Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Multiple Myeloma Treatment Market: Quality Assurance
  • FIG. 5 Global Multiple Myeloma Treatment Market, By Type, 2021
  • FIG. 6 Global Multiple Myeloma Treatment Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Multiple Myeloma Treatment Market, 2021
  • FIG. 8 Market Positioning of Key Multiple Myeloma Treatment Market Players, 2021
  • FIG. 9 Global Multiple Myeloma Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Multiple Myeloma Treatment Market, By Type, 2021 Vs 2030, %
  • FIG. 11 U.S. Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 France Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 China Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 India Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Multiple Myeloma Treatment Market (US$ Million), 2020 - 2030